Group 1 - CITIC Securities maintains a "Buy" rating for Huahong Semiconductor (01347.HK) with a target price of HKD 100, highlighting its leading position in specialty process wafer foundry and strong growth potential from capacity expansion and acquisitions [1] - CITIC Securities also maintains a "Buy" rating for SiHuan Pharmaceutical (00460.HK) with a target price of HKD 1.6, noting rapid growth in its medical aesthetic products and strong sales performance of new regenerative products [1] - GF Securities maintains a "Buy" rating for Yum China (09987.HK) with a target price of HKD 453.62, citing improved same-store sales and growth driven by new product iterations and marketing strategies [1] Group 2 - GF Securities initiates coverage on Laoputang Gold (06181.HK) with a "Buy" rating and a target price of HKD 775.64, emphasizing its leading position in handcrafted gold jewelry and strong growth potential from store expansion [2] - GF Securities initiates coverage on Yue Yuen Industrial (00551.HK) with a "Buy" rating and a target price of HKD 19.99, highlighting its status as the largest athletic shoe manufacturer and expected performance recovery [3] Group 3 - Cinda International maintains a "Buy" rating for Hesai Technology (02525.HK), noting its leadership in the global LiDAR market and significant growth in production and market share [4] - Zhongtai Securities initiates coverage on China Resources Land (01109.HK) with an "Accumulate" rating, reporting strong revenue and profit growth along with a healthy financial structure [5] Group 4 - First Shanghai initiates coverage on Jaxin International Resources (03858.HK) with a "Buy" rating and a target price of HKD 82.4, highlighting its world-class tungsten resources and strong profit growth potential [6] - Kaiyuan Securities initiates coverage on Beautiful Pastoral Medical Health (02373.HK) with a "Buy" rating, emphasizing its differentiated business model and effective customer acquisition strategies [7] Group 5 - CICC maintains an "Outperform" rating for Standard Chartered Group (02888.HK), noting better-than-expected Q2 2025 performance driven by significant growth in non-interest income [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四環醫藥控股集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000 ...

Group 1 - The core viewpoint of the news is that Hong Kong's innovative drug concept stocks experienced a collective rise, indicating positive market sentiment in the pharmaceutical sector [1] Group 2 - Jingtai Holdings (02228) saw an increase of 6.13%, with a latest price of 10.040 and a total market capitalization of 43.206 billion [2] - Hengrui Medicine (01276) rose by 4.63%, with a latest price of 74.550 and a total market capitalization of 494.803 billion [2] - SiHuan Pharmaceutical (00460) increased by 4.07%, with a latest price of 1.280 and a total market capitalization of 11.707 billion [2] - Innovent Biologics (01801) experienced a rise of 3.34%, with a latest price of 78.800 and a total market capitalization of 135.599 billion [2] - WuXi Biologics (02269) increased by 3.18%, with a latest price of 32.440 and a total market capitalization of 133.916 billion [2] - China National Pharmaceutical Group (01177) rose by 3.07%, with a latest price of 6.370 and a total market capitalization of 119.506 billion [2] - BeiGene (06160) saw an increase of 2.68%, with a latest price of 184.100 and a total market capitalization of 283.639 billion [2] - Kingstar Bio (01548) rose by 2.66%, with a latest price of 12.750 and a total market capitalization of 27.874 billion [2] - Genscript Biotech (01952) increased by 2.49%, with a latest price of 37.900 and a total market capitalization of 13.4 billion [2] - WuXi AppTec (02359) saw a rise of 2.13%, with a latest price of 100.800 and a total market capitalization of 300.763 billion [2]

Group 1 - The core viewpoint of the article highlights the significant rise in Hong Kong's innovative drug concept stocks, indicating a positive trend in the sector [2] - Jingtai Holdings experienced a surge of over 6%, reflecting strong investor interest and confidence in the company [2] - Hengrui Medicine saw an increase of over 5%, suggesting robust performance and market positioning [2] - Four Seasons Pharmaceutical rose by more than 4%, indicating a favorable market response [2] - Innovent Biologics and WuXi Biologics both increased by over 3%, showcasing the overall strength of the innovative drug sector [2] - BeiGene's stock rose by over 2%, further contributing to the positive sentiment in the market [2]

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].

格隆汇勾股大数据显示，腾讯控股(00700)、小米集团-W(01810)、三花智控(02050)、中远海控(01919)、 金山软件(03888)、快手-W(01024)、巨子生物(02367)、碧桂园服务(06098)、名创优品(09896)、四环医 药(00460)、明源云(00909)、津上机床中国(01651)、多点数智(02586)、科济药业-B(02171)、富智康集团 (02038)、趣致集团(00917)、汇通达网络(09878)、海吉亚医疗(06078)、心玮医疗-B(06609)、德康农牧 (02419)、绿城服务(02869)、捷利交易宝(08017)、歌礼制药-B(01672)、VITASOY INT'L(00345)、同道猎 聘(06100)、海尔智家(06690)、荃信生物-B(02509)、知行科技(01274)、连连数字(02598)、昊海生物科技 (06826)、锅圈(02517)、叮当健康(09886)、天伦燃气(01600)、中远海发(02866)、信利国际(00732)、绿茶 集团(06831)、思派健康(00314)、希玛医疗(03309)、枫叶教育(01317)、北 ...

四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...

格隆汇12月29日丨四环医药(00460.HK)公告，12月29日耗资1000.9万港元回购800万股。 ...

智通财经APP讯，四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 關於四環醫藥 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 購回股份 此 乃 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司， 統 稱 為「本集團」）作 出 的 自 願 公 告。 本 公 司 董 事 會（「董事會」）謹 此 宣 佈，根 據 本 公 司 股 東 於 二 零 二 五 年 六 月 六 日 舉 行 之 股 東 周 年 大 會 上 授 出 之 一 般 購 回 授 權（「購回授權」），其 擬 行 使 其 權 利 以 於 適 當 時 候 從 公 開 市 場 購 回 股 份。 董 事 會 進 一 步 宣 佈，根 據 購 回 授 權，本 公 司 於 二 零 二 五 年 ...